眼附属器黏膜相关淋巴组织结外边缘区淋巴瘤诊治中国专家共识(2023版)

Chinese expert consensus on the diagnosis and management of ocular adnexal extranodal marginal zone mucosa-associated lymphoid tissue lymphoma(2023 edition)

眼附属器黏膜相关淋巴组织结外边缘区(MALT)淋巴瘤是发生在眼附属器常见的恶性肿瘤,随着人口老龄化,眼附属器MALT淋巴瘤的发生率呈上升趋势。肿瘤组织侵犯眼附属器局部,容易导致眼部外观和功能的异常,影响患者的生活质量。目前眼附属器MALT淋巴瘤尚无统一的规范化诊疗指南,为了进一步提高眼附属器MALT淋巴瘤的规范化诊断和治疗水平,中国人体健康科技促进会细胞免疫治疗专业委员会、中国医师协会眼科医师分会眼肿瘤专业委员会、中国医疗保健国际交流促进会影像医学分会、中国抗癌协会肿瘤与微生态专业委员会学会和北京癌症防治学会淋巴瘤免疫治疗专业委员会专家联合编写了首个眼附属器MALT淋巴瘤诊治中国专家共识(2023版),以期为临床提供指导。

Ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue(OAML)is a common malignant tumor that affects the ocular adnexal region.The incidence of OAML is increasing due to the aging population.The tumor invades the ocular adnexal region,which can result in abnormal ocular appearance and function,thereby reducing the quality of life.Currently,there is no standardized diagnosis and management guideline for OAML.To enhance the standardization of diagnosis and management in OAML,a collaborative effort was undertaken by esteemed organizations in China.The Cellular Immune Therapy Committee of China Association for Promotion of Health Science and Technology,the Ocular Tumor Committee of Chinese Medical Doctor Association for Ophthalmologist Branch,the Imaging Medicine Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare,the Tumor and Microecology Professional Committee of China Anti-cancer Association,and the Lymphoma Immunotherapy Committee of Beijing Cancer Prevention Society jointly convened a panel of experts to develop the inaugural"Chinese Expert Consensus on the Diagnosis and Management of ocular adnexal extranodal marginal zone mucosa-associated lymphoid tissue lymphoma(2023 edition)".